Cocrystal reports favorable preliminary safety for CDI-988 (Phase 1) and CC-42344 (Phase 2a) antivirals

Cocrystal Pharma, Inc.

CDI-988 (pan-norovirus/coronavirus 3CL protease inhibitor) Phase 1 in Australia shows favorable safety in single-ascending dose cohorts.
CC-42344 (influenza A PB2 inhibitor) Phase 2a in UK shows favorable tolerability in first cohort of challenge study.
Cocrystal expects to report topline results for both Phase 1 and Phase 2a studies in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.